Brain zaps boost balance in breast cancer survivors
NCT ID NCT06610617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether a non-invasive brain stimulation technique called tDCS could improve balance and thinking in older women who had chemotherapy for breast cancer. 48 women aged 50-85 took part. The results will show if this approach can help with common side effects like poor balance and mild cognitive issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
48 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria for breast, ovarian and endometrial cancer survivors: * Women aged 50-85 years * Breast, ovarian and/or endometrial cancer survivors, stages I-IV * Completion of taxane chemotherapy treatment. Taxane combined with a history of anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy is permitted. Receiving platin based agents is permitted. * Ability to walk without an assistive device * Ability to speak and read English * Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD) * No history of a other cancer, with the exception that non-melanoma skin cancers are permitted * Own a device with capability to sync the Fitbit Inclusion criteria for older cancer-free women: * Women aged 50-85 years * Ability to walk without an assistive device * Ability to speak and read English * Without neurological disease * No history of cancer * Own a device with capability to sync the Fitbit Inclusion for older, taxane-treated breast, ovarian, and endometrial cancer survivors (OTTBCS) performing a single visit: * Women aged 50-85 years * Breast, ovarian and/or endometrial cancer survivors, stages I-IV * Completion of taxane chemotherapy treatment. Taxane combined with a history of anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy is permitted. Receiving platin based agents is permitted. * Ability to walk without an assistive device * Ability to speak and read English * Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD) * No history of a other cancer, with the exception that non-melanoma skin cancers are permitted * Own a device with capability to sync the Fitbit Exclusion criteria for cancer survivors and older women: * Inability to stand or walk unassisted for 60 seconds * Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance * Any unstable medical condition * Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder. Cognitive status assessed via the Telephone Interview of Cognitive Status (mTICS). We will exclude those with marked dementia (score\<31) * Chronic vertigo * Myocardial infarction within the past six months * Any history of brain or spine surgery, known hearing, visual, or vestibular impairment * Active chemotherapy, radiation (see below) * Currently taking anti-epileptic medication * Known Brain Metastasis Exclusion for older, taxane-treated breast, ovarian, and endometrial cancer survivors (OTTBCS) performing a single visit: * Inability to stand or walk unassisted for 60 seconds * Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance * Any unstable medical condition * Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder. Cognitive status assessed via the Telephone Interview of Cognitive Status (mTICS). We will exclude those with marked dementia (score\<31) * Chronic vertigo * Myocardial infarction within the past six months * Known hearing, visual, or vestibular impairment * Active chemotherapy, radiation (see below) * Known Brain Metastasis Additional Criteria for cancer survivors: * The following criteria is only exclusionary if participant will receive tDCS. Contraindications to transcranial direct simulation (tDCS), including reported seizure within the past 2 years, Currently taking anti-epileptic medication, active use of neuro-active drugs, metal objects anywhere in the head or the neck, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp. Any history of brain or spine surgery * Active chemotherapy after the first line of 6 cycles is completed will be eligible.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can watching your own brain activity on a screen sharpen memory after childhood brain cancer?
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?